AnaptysBio's imsidolimab shows promise in GPP

San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) saw its shares edge up 3.6% to $19.95, after it released results from the Phase III GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (interleukin (IL)-36R MAb) in patients with generalized pustular psoriasis (GPP) flares.

AnaptysBio noted that the investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile. The drug has previously disappointed in an earlier trial in severe palmoplantar pustulosis and in the treatment of moderate-to-severe acne.

Results showed that 53.3% of the 15 patients who received the 750mg dose achieved GPPPGA 0/1 (clear or almost clear) at week four compared with 13.3% of the 15 patients on placebo. Additionally, 66.7% of the placebo group exited the trial early, crossed-over to the GEMINI-2 trial and were eligible to receive rescue therapy with a single dose of 750mg IV imsidolimab.